1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Merck KGaA
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Rigel Pharmaceuticals Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Calliditas Therapeutics AB
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Anthera Pharmaceuticals, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. ChemoCentryx, Inc.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Pfizer Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Apellis Pharmaceuticals
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Reata Pharmaceuticals, Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Omeros Corporation
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Visterra, Inc.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Novartis AG
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Mallinckrodt
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Shire
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. IGAN Biosciences, Inc.
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Alexion Pharmaceuticals
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Retrophin, Inc
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Genosco
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
List of Tables
List of Figures